GLP1R and diabetes mellitus: However, beginning with publication of the EMPA-REG OUTCOME [2] and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trials [3], multiple trials and observational studies have shown cardiovascular risk reduction with the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) [4] and glucagonlike peptide-1 receptor agonists (GLP-1 RA) [5].